Biogen has appointed Tim Power as Vice President and Head of Investor Relations, effective December 9, 2024. In this role, Mr. Power will report directly to Michael McDonnell, the company’s Executive Vice President and Chief Financial Officer.
I am excited to welcome Tim to Biogen, said McDonnell. His deep expertise in investor relations and his proven ability to effectively communicate complex business strategies, combined with his strong background in translating breakthrough scientific advancements, will be invaluable as we continue our mission to return to sustainable growth.
With over two decades of experience in finance and investor relations, Mr. Power most recently served as Vice President and Head of Investor Relations at Bristol Myers Squibb (BMS), a leading global biopharmaceutical company. During his tenure at BMS, Mr. Power played a critical role in managing the company’s global relationships with the investment community. He was instrumental in communicating the company’s strategy and financial performance, as well as guiding investor messaging during pivotal corporate events, including the landmark acquisition of Celgene—one of the largest mergers and acquisitions in biopharmaceutical history.
Before leading investor relations at BMS, Mr. Power held several other strategic and financial positions, including Director roles in Portfolio & Asset Strategy and Strategic Planning. He also gained experience in strategic consulting and engineering roles at companies such as Strategic Decisions Group and Shell Oil Company.
Mr. Power’s educational background includes an MBA in Finance from The Wharton School at the University of Pennsylvania. He also holds a PhD in Chemical Engineering from Carnegie Mellon University and completed his undergraduate studies in Chemical Engineering at University College Dublin, Ireland.
“We are confident that Tim’s experience and skills will strengthen Biogen’s communications with investors and enhance our strategy moving forward,” said McDonnell. “At the same time, I want to extend my sincere thanks to Steve Amato, who has stepped in as the interim lead for our Investor Relations team. His leadership during this transition has been instrumental in maintaining strong communication with our investors, and we are fortunate to have him on the team.”
Biogen’s appointment of Tim Power reflects the company’s ongoing commitment to strengthening its leadership team as it works toward its goal of returning to long-term growth, following a period of strategic transformation. The combination of Mr. Power’s expertise in investor relations and his solid background in both financial and strategic communication positions him well to help Biogen navigate its future endeavors and maintain transparent relationships with its shareholders.
With Mr. Power’s leadership, Biogen aims to build stronger connections with investors, communicate the company’s evolving strategy more effectively, and ensure consistent messaging during critical moments in the company’s growth trajectory.
As Biogen looks ahead, the leadership team is focused on maintaining investor confidence while progressing with its innovations in the biopharmaceutical sector. The appointment of Mr. Power signals Biogen’s ongoing commitment to strengthening its investor relations function and its resolve to drive sustainable, long-term growth in the face of an evolving healthcare landscape.
